Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug

News provided by

Clearmind Medicine

September 21, 2021

The R&D projectwith Yissum Research Development Company will contribute to Clearmind’s IPportfolio


TORONTO,September 21, 2021 -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind”or the "Company"), a psychedelic medicine biotech companyfocused on the discovery and development of novel psychedelic-derivedtherapeutics to solve widespread and undertreated health problems, is pleased toannounce it has established a research and development project with YissumResearch Development Company (“Yissum”), the technology transfer companyof The Hebrew University of Jerusalem. The collaboration will focus ondeveloping novel, innovative, patentable psychedelics as potential drugcandidates to expand Clearmind’s IP portfolio.


Yissumis known for its ability to discover, analyze and design advanced molecularscaffolds to serve as common platforms for synthesizing various structurallyrelated compounds as potential therapeutic agents and drug candidates.


Accordingto the terms of the agreement, The Hebrew University researchers, professorsDmitry Tsvelikhovsky, Masha Niv and Avi Priel, will work together toinvestigate and innovate synthetic novel analogs of known psychedeliccompounds, conduct in silico 3D docking studies and rational design, and screenthe compounds in an in vitro platform.


AdiZuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “This isan important partnership for Clearmind. The academic/technology transfer modelis responsible for many medical breakthroughs, and the Hebrew University-Yissumpartnership is one of the most prolific in the field. I am certain that ourcollaboration will yield many potential candidates for further evaluation.”


“Yissumis looking forward to collaborating with Clearmind in its mission to discover novelpsychedelic compounds. We have assigned our top researchers from multiplefields to this project, and I am confident their broad expertise and know-how willfacilitate Clearmind’s ability to expand their pipeline portfolio,”said Dr. Ilya Pittel, VP of business development at Yissum Research DevelopmentCompany.


ProfessorTsvelihovsky added, “Professors Avi Priel and Masha Niv and I are excited towork with the team at Clearmind to create unique synthetic compounds for thedevelopment of novel GPCR-focused therapeutics. We believe psychedelics aregoing to revolutionize the treatment of mental health, and Clearmind's plansput it on the leading edge of innovation in the field. We are quite optimisticthat our efforts will lead to new psychotherapy drug candidates.”

About Yissum Research Development Company


Yissumis the technology transfer company of The Hebrew University of Jerusalem.Founded in 1964, it serves as a bridge between cutting-edge academic researchand a global community of entrepreneurs, investors and industry. Yissum’smission is to benefit society by converting extraordinary innovations andtransformational technologies into commercial solutions that address our mosturgent global challenges. Yissum has registered over 10,875 patents globally,licensed over 1,140 technologies and has spun out more than 191 companies.Yissum’s business partners span the globe and include companies such as BostonScientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft,Novartis and many more. For further information, please visit


About the Hebrew University of Jerusalem


TheHebrew University of Jerusalem is Israel's first university, formed in 1918 andopened in 1925. Today, there are over 23,000 students enrolled at the university,including undergraduates, master's degree students and doctoral candidates. Theuniversity has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram)Campus, and Ein Kerem, all in Jerusalem, and Robert H. Smith Faculty ofAgriculture, Food and the Environment, located in Rehovot. Hebrew UniversityAlumni are invited to visit


AboutClearmind Medicine Inc.


Clearmindis a psychedelic pharmaceutical biotech company focused on the discovery anddevelopment of novel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is to researchand develop psychedelic-based compounds and attempt to commercialize them asregulated medicines, foods or supplements.


TheCompany’s intellectual portfolio currently consists of two patent families. Thefirst, "Binge Behavior Regulators," has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute,” has been approved for aEuropean patent, with pending applications in the U.S., China and India. TheCompany intends to seek additional patents for its compounds whenever warrantedand will remain opportunistic regarding the acquisition of additional intellectualproperty to build its portfolio.


Sharesof Clearmind are listed for trading on the Canadian Securities Exchange underthe symbol "CMND" and the Frankfurt Stock Exchange under thesymbol “CWYO.”


For further information, please contact:

Investor Relations,

Telephone: (778) 400-5347

General Inquiries,




Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company's business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management's reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.


Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.


Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of, the securities in any province inwhich such offer, solicitation or sale would be unlawful. The securitiesissued, or to be issued, under the Private Placement have not been, and willnot be, registered under the United States Securities Act of 1933, as amended,and may not be offered or sold in the United States absent registration or anapplicable exemption from registration requirements.


Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) accepts responsibilityfor the adequacy or accuracy of this release.